^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Sulanda (surufatinib)

    i
    Other names: HMPL-012, HMPL012, HMPL 012
    Company:
    Hutchmed
    Drug class:
    VEGFR-2 inhibitor, VEGFR inhibitor, CSF-1R inhibitor, FGFR1 inhibitor, VEGFR-1 inhibitor, VEGFR-3 inhibitor
    Related drugs:
    7d
    Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer (clinicaltrials.gov)
    P3, N=106, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P3 trial
    |
    gemcitabine • capecitabine • albumin-bound paclitaxel • Sulanda (surufatinib)
    8d
    Immunosuppressive Environment of Pancreatic NENs-A Review. (PubMed, Biomedicines)
    Therapies using tyrosine kinase inhibitors, such as sunitinib and newer drugs (lenvatinib, surufatinib, cabozantinib), may partially normalize the tumor's disrupted vascular architecture and thus increase its susceptibility to immunological interventions. In the coming years, it will be crucial not only to overcome the immunosuppressive nature of the TME but also to identify predictive biomarkers that will allow for more precise patient selection. This approach may open the way to more effective, personalized therapies for pNENs.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • CD276 (CD276 Molecule) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1)
    |
    sunitinib • Lenvima (lenvatinib) • Cabometyx (cabozantinib tablet) • Sulanda (surufatinib)
    24d
    HMPL-012-SPRING-P105: Efficacy and Safety of Surufatinib Combined With Gemcitabine and Albumin-bound Paclitaxel in the Peri-operative Treatment of Pancreatic Cancer (clinicaltrials.gov)
    P2, N=29, Active, not recruiting, Tianjin Medical University Cancer Institute and Hospital | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    gemcitabine • albumin-bound paclitaxel • Sulanda (surufatinib)
    1m
    Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine Neoplasms (ChiCTR2500114518)
    P4, N=350, Not yet recruiting, Zhongshan Hospital Affiliated to Fudan University; Zhongshan Hospital Affiliated to Fudan University
    New P4 trial
    |
    Sulanda (surufatinib)
    1m
    Phase Ⅱ Clinical Study of Surufatinib Combined with Temozolomide as First-line Therapy for Pulmonary Neuroendocrine Tumors (ChiCTR2600116780)
    P2, N=27, Not yet recruiting, The Second Affiliated hospital of Fujian Medical University; The Second Affiliated hospital of Fujian Medical University
    New P2 trial
    |
    temozolomide • Sulanda (surufatinib)
    1m
    Surufatinib combined with toripalimab, albumin - bound paclitaxel and radiotherapy for first - line treatment of advanced esophageal cancer:A single - arm, open - label, phase II clinical study (ChiCTR2600116673)
    P2, N=30, Completed, Department of Radiation Oncology, the First Medical Center, Chinese People's Liberation Army (PLA) General Hospital; The First Medical Center, Chinese
    New P2 trial
    |
    Loqtorzi (toripalimab-tpzi) • albumin-bound paclitaxel • Sulanda (surufatinib)
    1m
    Surufatinib for advanced or metastatic chemotherapy-refractory thymic malignancies: a single-arm, single-center, phase II study (ChiCTR2600116776)
    P2, N=20, Completed, Zhongshan Hospital, Fudan University; Zhongshan Hospital, Fudan University
    New P2 trial
    |
    Sulanda (surufatinib)
    1m
    Surufatinib Combined With Chemo Versus Surufatinib in the Treatment of Pulmonary Neuroendocrine Tumors (clinicaltrials.gov)
    P2, N=96, Recruiting, Shanghai Chest Hospital
    New P2 trial
    |
    NCAM1 (Neural cell adhesion molecule 1)
    |
    carboplatin • temozolomide • capecitabine • Sulanda (surufatinib)
    2ms
    Systemic Therapy for Advanced Pheochromocytoma and Paraganglioma: Real-World Evidence from a Single Center Cohort. (PubMed, Endocr Relat Cancer)
    In the first-line setting, targeted therapy and SSAs were associated with longer PFS than chemotherapy, with surufatinib and lanreotide showing favorable disease control. SDHx pathogenic variant status did not show a clear association with response to TKIs or temozolomide, underscoring the need for validation in larger cohorts.
    Journal • HEOR • Real-world evidence
    |
    SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B)
    |
    temozolomide • Sulanda (surufatinib)
    2ms
    2023-012-00CH1: A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer (clinicaltrials.gov)
    P2/3, N=502, Recruiting, Hutchmed | Trial completion date: Aug 2027 --> May 2028 | Trial primary completion date: Aug 2027 --> May 2028
    Trial completion date • Trial primary completion date
    |
    gemcitabine • AiRuiKa (camrelizumab) • albumin-bound paclitaxel • Sulanda (surufatinib)
    3ms
    ZSPAC-17: Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine Neoplasms (clinicaltrials.gov)
    P4, N=350, Recruiting, Shanghai Zhongshan Hospital | Not yet recruiting --> Recruiting
    Enrollment open • Real-world evidence
    |
    Sulanda (surufatinib)
    3ms
    Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma (clinicaltrials.gov)
    P2, N=36, Recruiting, Sun Yat-sen University | Trial completion date: Nov 2025 --> Dec 2027 | Trial primary completion date: Nov 2024 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    Tyvyt (sintilimab) • capecitabine • Sulanda (surufatinib)